📊 NAGE Key Takeaways
Is Niagen Bioscience, Inc. (NAGE) a Good Investment?
Niagen demonstrates strong revenue growth (29.9% YoY) and healthy gross margins (63.5%), supported by a fortress balance sheet with $66.5M cash and minimal debt. However, a critical concern emerges: operating cash flow is -$1.2M despite $6.3M net income, indicating potential earnings quality issues or working capital stress that demands immediate clarification.
Niagen Bioscience shows strong fundamental momentum: ~30% revenue growth, expanding profitability, and double‑digit ROE/ROA supported by a net‑cash, low‑leverage balance sheet. High gross margins, excellent cash conversion, and minimal capex needs position the company to compound free cash flow if growth persists.
Niagen Bioscience, Inc. Key Strengths (NAGE)
- Strong revenue growth at 29.9% YoY with $31.5M revenue base
- Excellent gross margin of 63.5% indicates pricing power and operational efficiency
- Fortress balance sheet with $66.5M cash, 0.12x debt-to-equity, and 4.61x current ratio
- Robust liquidity with 3.55x quick ratio and 68.5x interest coverage
- EPS growth of 81.8% YoY demonstrates bottom-line expansion
- High gross margin (64.3%) with positive operating leverage
- Strong balance sheet with net cash and low debt (0.13x D/E)
- Consistent free cash flow generation and very high interest coverage
NAGE Stock Risks: Niagen Bioscience, Inc. Investment Risks
- Critical red flag: negative operating cash flow (-$1.2M) vs. positive net income ($6.3M) suggests earnings quality concerns or significant working capital absorption
- Negative free cash flow (-$1.3M FCF margin of -4.3%) despite profitability indicates cash generation problems
- Underwhelming returns: 7.7% ROE and 5.5% ROA are modest given the strong balance sheet
- Extremely low capital expenditure ($147K) suggests minimal reinvestment in growth or R&D capacity
- Large disconnect between accounting profits and cash generation requires immediate disclosure review
- Sustainability of ~30% revenue growth and potential customer/product concentration
- Regulatory and compliance risks inherent to medicinal/botanical products
- Competitive intensity and input cost pressures could compress margins
Key Metrics to Watch
- Operating cash flow trend and working capital dynamics
- Quality of earnings: reconciliation between net income and operating cash flow
- Revenue growth sustainability and gross margin trajectory
- Capital expenditure and R&D investment levels
- Accounts receivable and inventory turnover metrics
- Revenue growth (YoY)
- Free cash flow margin
Niagen Bioscience, Inc. (NAGE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.61x current ratio provides a solid financial cushion.
NAGE Profit Margin, ROE & Profitability Analysis
NAGE vs Materials Sector: How Niagen Bioscience, Inc. Compares
How Niagen Bioscience, Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Niagen Bioscience, Inc. Stock Overvalued? NAGE Valuation Analysis 2026
Based on fundamental analysis, Niagen Bioscience, Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Niagen Bioscience, Inc. Balance Sheet: NAGE Debt, Cash & Liquidity
NAGE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Niagen Bioscience, Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.11 reflects profitable operations.
NAGE Revenue Growth, EPS Growth & YoY Performance
NAGE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $30.5M | $5.1M | $0.06 |
| Q3 2025 | $25.6M | $1.4M | $0.02 |
| Q2 2025 | $22.7M | -$15.0K | $0.00 |
| Q1 2025 | $22.2M | -$492.0K | $-0.01 |
| Q3 2024 | $19.5M | -$959.0K | $-0.01 |
| Q2 2024 | $20.3M | -$15.0K | $0.00 |
| Q1 2024 | $22.2M | -$492.0K | $-0.01 |
| Q3 2023 | $17.1M | -$959.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Niagen Bioscience, Inc. Dividends, Buybacks & Capital Allocation
NAGE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Niagen Bioscience, Inc. (CIK: 0001386570)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NAGE
What is the AI rating for NAGE?
Niagen Bioscience, Inc. (NAGE) has a Combined AI Grade of A from Claude (B) and ChatGPT (A) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAGE's key strengths?
Claude: Strong revenue growth at 29.9% YoY with $31.5M revenue base. Excellent gross margin of 63.5% indicates pricing power and operational efficiency. ChatGPT: High gross margin (64.3%) with positive operating leverage. Strong balance sheet with net cash and low debt (0.13x D/E).
What are the risks of investing in NAGE?
Claude: Critical red flag: negative operating cash flow (-$1.2M) vs. positive net income ($6.3M) suggests earnings quality concerns or significant working capital absorption. Negative free cash flow (-$1.3M FCF margin of -4.3%) despite profitability indicates cash generation problems. ChatGPT: Sustainability of ~30% revenue growth and potential customer/product concentration. Regulatory and compliance risks inherent to medicinal/botanical products.
What is NAGE's revenue and growth?
Niagen Bioscience, Inc. reported revenue of $31.5M.
Does NAGE pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
Where can I find NAGE SEC filings?
Official SEC filings for Niagen Bioscience, Inc. (CIK: 0001386570) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAGE's EPS?
Niagen Bioscience, Inc. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NAGE's fundamental grade?
Based on our AI fundamental analysis in May 2026, Niagen Bioscience, Inc. has a A grade with 71% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NAGE stock overvalued or undervalued?
Valuation metrics for NAGE: ROE of 7.7% (sector avg: 14%), net margin of 20.1% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is NAGE's AI grade for 2026?
Our dual AI analysis gives Niagen Bioscience, Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NAGE's free cash flow?
Niagen Bioscience, Inc.'s operating cash flow is $-1.2M, with capital expenditures of $147.0K. FCF margin is -4.3%.
How does NAGE compare to other Materials stocks?
Vs Materials sector averages: Net margin 20.1% (avg: 10%), ROE 7.7% (avg: 14%), current ratio 4.61 (avg: 1.6).